{
    "clinical_study": {
        "@rank": "112763", 
        "arm_group": [
            {
                "arm_group_label": "Phase 1: Dose Level 1", 
                "arm_group_type": "Experimental", 
                "description": "Ibrutinib PO+ Lenalidomide (PO) + Rituximab (IV)"
            }, 
            {
                "arm_group_label": "Phase 1: Dose Level 2", 
                "arm_group_type": "Experimental", 
                "description": "Ibrutinib PO+ Lenalidomide (PO) + Rituximab (IV)"
            }, 
            {
                "arm_group_label": "Phase 1: Dose Level 3", 
                "arm_group_type": "Experimental", 
                "description": "Ibrutinib PO+ Lenalidomide (PO) + Rituximab (IV)"
            }, 
            {
                "arm_group_label": "Phase 2- Arm A", 
                "arm_group_type": "Experimental", 
                "description": "Ibrutinib PO+ Lenalidomide (PO) + Rituximab (IV)"
            }, 
            {
                "arm_group_label": "Phase 2 - Arm B", 
                "arm_group_type": "Experimental", 
                "description": "Ibrutinib PO+ Lenalidomide (PO)"
            }
        ], 
        "brief_summary": {
            "textblock": "This Phase 1b/2 study is designed to assess the safety and efficacy of ibrutinib in\n      combination with lenalidomide and rituximab in subjects with relapsed/refractory Diffuse\n      Large B-Cell Lymphoma   (DLBCL) not eligible for transplant."
        }, 
        "brief_title": "Ibrutinib in Combination With Lenalidomide, With and Without Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma", 
        "completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Relapsed Diffuse Large B-Cell Lymphoma", 
            "Refractory Diffuse Large B-Cell Lymphoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Lymphoma", 
                "Lymphoma, B-Cell", 
                "Lymphoma, Large B-Cell, Diffuse"
            ]
        }, 
        "detailed_description": {
            "textblock": "Phase 1b: In the dose escalation portion of the study, up to three cohorts may be explored\n      and lenalidomide dose escalation will follow the 3+3+3 principle for MTD determination.\n\n      Phase 2: This will be conducted as an international, multicenter, randomized open-label\n      study.  Eligible subjects will be randomized in a 1:1 ratio into 2 arms to receive either\n      ibrutinib, lenalidomide and rituximab (Treatment Arm A) or ibrutinib and lenalidomide\n      (Treatment Arm B)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Pathologically confirmed relapsed/ refractory DLBCL\n\n          -  Must have previously received first line treatment regimen\n\n          -  Must be ineligible for high dose therapy/ stem cell transplantation\n\n          -  Measurable disease sites on CT scan (>1.5 cm in longest dimension)\n\n          -  PT/INR <1.5 x ULN and PTT (aPTT) <1.5 x ULN\n\n          -  Men and women \u226518 years of age\n\n          -  ECOG < 2\n\n          -  Adequate hepatic and renal function:\n\n               1. AST or ALT \u22642.5 x ULN\n\n               2. Estimated creatinine clearance (Cockcroft-Gault) >60 mL/min.\n\n          -  Adequate hematologic function:\n\n               1. ANC >1,500 cells/mm3\n\n               2. Plt >75,000 cells/mm3\n\n               3. Hgb >8.0 g/dL\n\n        Exclusion Criteria:\n\n          -  Medically apparent central nervous system lymphoma or leptomeningeal disease\n\n          -  History of allogeneic stem-cell (or other organ) transplantation\n\n          -  Any chemotherapy, external beam radiation therapy, or anticancer antibodies within 2\n             weeks\n\n          -  Radio- or toxin-immunoconjugates within 10 weeks\n\n          -  Concurrent enrollment in another therapeutic investigational study or have\n             previously taken ibrutinib"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "130", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 10, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02077166", 
            "org_study_id": "PCYC-1123-CA"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Phase 1: Dose Level 1", 
                    "Phase 1: Dose Level 2", 
                    "Phase 1: Dose Level 3", 
                    "Phase 2- Arm A", 
                    "Phase 2 - Arm B"
                ], 
                "intervention_name": "Ibrutinib", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Phase 1: Dose Level 1", 
                    "Phase 1: Dose Level 2", 
                    "Phase 1: Dose Level 3", 
                    "Phase 2- Arm A", 
                    "Phase 2 - Arm B"
                ], 
                "intervention_name": "Lenalidomide", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Phase 1: Dose Level 1", 
                    "Phase 1: Dose Level 2", 
                    "Phase 1: Dose Level 3", 
                    "Phase 2- Arm A"
                ], 
                "intervention_name": "Rituximab", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Rituximab", 
                "Thalidomide", 
                "Lenalidomide"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 5, 2014", 
        "location": [
            {
                "contact": {
                    "email": "kaulaskk@karmanos.org", 
                    "last_name": "Khushbu Kaulaskar"
                }, 
                "facility": {
                    "address": {
                        "city": "Detroit", 
                        "country": "United States", 
                        "state": "Michigan"
                    }, 
                    "name": "Karmanos Cancer Institute"
                }, 
                "investigator": {
                    "last_name": "Radhakrishnan Ramchandren, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Rebecca.boucher@usoncology.com", 
                    "last_name": "Rebecca Boucher"
                }, 
                "facility": {
                    "address": {
                        "city": "Las Vegas", 
                        "country": "United States", 
                        "state": "Nevada"
                    }, 
                    "name": "Comprehensive Cancer Center of Nevada"
                }, 
                "investigator": {
                    "last_name": "Edwin Kingsley, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Skdiry@hackensackumc.org", 
                    "last_name": "Sabrina Kdiry"
                }, 
                "facility": {
                    "address": {
                        "city": "Hackensack", 
                        "country": "United States", 
                        "state": "New Jersey"
                    }, 
                    "name": "Hackensack University Medical Center"
                }, 
                "investigator": {
                    "last_name": "Andre Goy, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jon3001@med.cornell.edu", 
                    "last_name": "Jonathan Navi"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York"
                    }, 
                    "name": "Weill Cornell Medical Center"
                }, 
                "investigator": {
                    "last_name": "Jia Ruan, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "ktoth@zangcenter.com", 
                    "last_name": "Kathi Toth, RN, OCN"
                }, 
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio"
                    }, 
                    "name": "Mid-Ohio Oncology/ Hematology"
                }, 
                "investigator": {
                    "last_name": "Mark Knapp, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "5", 
        "official_title": "A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With Lenalidomide, With and Without Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma", 
        "overall_contact": {
            "email": "medinfo@pcyc.com", 
            "last_name": "Anh Tran", 
            "phone": "855-427-8846"
        }, 
        "overall_official": {
            "affiliation": "Pharmacyclics", 
            "last_name": "Jutta K. Neuenburg, MD, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Phase 1: Maximally tolerated dose (MTD) of lenalidomide in combination with ibrutinib and rituximab, determined by dose-limiting toxicities (DLT) graded using the NCI CTCAE version 4.0", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 9 months"
            }, 
            {
                "measure": "Phase 2: Overall response (OR)", 
                "safety_issue": "No", 
                "time_frame": "Up to 36 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02077166"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Phase 1: Overall response (OR)", 
                "safety_issue": "No", 
                "time_frame": "Up to 36 months"
            }, 
            {
                "measure": "Phase 2: Duration of response (DOR)", 
                "safety_issue": "No", 
                "time_frame": "Up to 36 months"
            }, 
            {
                "measure": "Phase 2: Progression free survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "Up to 36 months"
            }, 
            {
                "measure": "Phase 2: Overall survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "Up to 36 months"
            }, 
            {
                "measure": "Phase 2: Complete response (CR)", 
                "safety_issue": "No", 
                "time_frame": "Up to 36 months"
            }, 
            {
                "measure": "Phase 2: Toxicities by attribute and grade, assessed using NCI CTCAE version", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 36 months"
            }
        ], 
        "source": "Pharmacyclics", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Janssen Research & Development, LLC", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Celgene Corporation", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "Pharmacyclics", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}